Fda Overhaul Ahead?

Republicans and industries clamoring for regulatory easing at the Food & Drug Administration have an unexpected ally. Representative Ron Wyden (D-Ore.), a hero of consumer advocates, has embraced key changes. He favors less pre-approval product testing, fewer export restrictions on unapproved medical devices, and shifting some FDA reviews to outside testing labs. Many Democrats and consumer groups fear such moves could lessen food and medical safety.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.